Pembrolizumab-Based Regimen Yields PFS Benefit in Platinum-Resistant Ovarian Cancer

MSD's Phase III trial of Keytruda meets endpoint for treating ovarian cancer

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its primary goal.The post MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer appeared first on Clinical Trials Arena.

Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer

Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.

Pembrolizumab Improves PFS in Recurrent Ovarian Cancer

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end point of progression-free survival.

Pembrolizumab-Based Regimen Yields PFS Benefit in Platinum-Resistant Ovarian Cancer

Pembrolizumab/paclitaxel with or without bevacizumab improved PFS vs placebo/chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer.